Videos

Thomas Crawford, MD, discusses the classification of different phenotypes of SMA and comments on the degree to which these classifications are relevant to treatment approaches.

The neurologist from Mayo Clinic discussed his abstract at AAN 2021 comparing stroke rates in patients with cerebral amyloid antipathy given treatment with aspirin.

The director and founder of the Sleep Centers of Middle Tennessee discussed strategies to achieve long term adherence to cPAP from patients with obstructive sleep apnea.

The consultant in the Department of Neurology at Mayo Clinic discussed the mechanisms of action researchers should key in on for patients with Parkinson disease.

Experts in progressive multiple sclerosis summarize the phase 2 SPRINT-MS trial and the rationale for treating patients with ibudilast.

A discussion of how experts treat nonactive multiple sclerosis in terms of trial results or symptom management and how decisions are based on patient age.

The professor of health science at the Medical University of South Carolina detailed the limits of what can be achieved with behavioral interventions for the symptoms of dementia.

The senior investigator at the National Institutes of Neurological Disorders and Stroke spoke about further research his lab is conducting into MS mechanisms.

Key opinion leaders in neurology discuss the safety and efficacy of apomorphine hydrochloride and provide insights into the advantages and disadvantages of its subcutaneous formulation.

Laxman Bahroo, DO and Mindy K. Bixby, DO define OFF episodes in Parkinson’s Disease and discuss how they are often unpredictable and variable in their severity.

Jill Dehlin, RN, a patient with migraine, talks about her experience receiving a subcutaneous injectable CGRP inhibitor, and neurologist Jessica Ailani, MD, explains what she counsels her patients on when prescribing a newer injectable treatment. 

Jessica Ailani, MD, a neurologist from MedStar Health, shares insight on best practices for dosing therapies used to treat migraine and implications for combining drugs together.

The assistant professor of neurology at Thomas Jefferson University discussed the potential and feasibility of brain implants in patients with stroke.

The senior director of patient management, care, and rehabilitation research at the National MS Society discussed symptoms of progressive MS that need more attention and research.

Tanuja Chitnis, MD reviews the 2018 AAN guidelines on disease-modifying therapies and discusses goals of therapy when selecting first-line treatments and monitoring response in pediatric multiple sclerosis.

Experts in multiple sclerosis discuss the importance of a multidisciplinary approach for pediatric patients and emphasize the role of social workers, psychologists, and support groups for patients and families.  

Expert neurologists discuss the variability of signs and symptoms as well as other factors to consider when diagnosing patients with amyotrophic lateral sclerosis (ALS).

A panel of key opinion leaders in neurology provides an overview of the prevalence of amyotrophic lateral sclerosis (ALS) and discusses potential causes and risk factors.

The postdoctoral researcher at Columbia University discussed the use of the DISCO-MS survey and its potential for future research projects.

The director and founder of the Sleep Centers of Middle Tennessee discussed the OSAinHome program that his practice has developed.

Richard describes the journey of his diagnosis with multiple sclerosis.

The professor of neurology at Johns Hopkins University, and a member of the Curing Coma Campaign’s Scientific Steering Committee spoke to the current limitations of clinical trials in coma.

The consultant in the Department of Neurology at Mayo Clinic discussed the advancements of Parkinson disease knowledge and treatment over the past 2 decades.

The professor of health science at the Medical University of South Carolina spoke to the dire need for more therapeutic approaches to treat some of the most difficult symptoms of dementia.

Neurology News Network for the week ending April 10, 2021.

The duo from the National Institutes of Health discussed how monitoring and treating paramagnetic rim lesions can improve patient care in multiple sclerosis.

The use of mass spectrometry is the gold standard in amyloid proteins.

Various types of biopsies to diagnosis hereditary ATTR amyloidosis are discussed.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine detailed the reasons behind the lack of research on social determinants of health on stroke outcomes.

The professor of neurology at Johns Hopkins University, and a member of the Curing Coma Campaign’s Scientific Steering Committee shared her insight into the current management of coma and the need for better prognostication.